Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN – Get Free Report) was the recipient of a significant decrease in short interest during the month of July. As of July 15th, there was short interest totalling 16,000 shares, a decrease of 49.4% from the June 30th total of 31,600 shares. Currently, 0.3% of the company’s shares are sold short. Based on an average daily volume of 49,400 shares, the days-to-cover ratio is presently 0.3 days.
Wall Street Analyst Weigh In
Separately, Chardan Capital reiterated a “buy” rating and issued a $30.00 target price on shares of Sonnet BioTherapeutics in a research note on Tuesday, May 28th.
View Our Latest Report on SONN
Sonnet BioTherapeutics Price Performance
Sonnet BioTherapeutics (NASDAQ:SONN – Get Free Report) last announced its quarterly earnings results on Tuesday, May 14th. The company reported $0.07 earnings per share for the quarter. Sonnet BioTherapeutics had a negative return on equity of 382.31% and a negative net margin of 11,187.19%. On average, equities analysts anticipate that Sonnet BioTherapeutics will post -2.14 EPS for the current fiscal year.
Sonnet BioTherapeutics Company Profile
Sonnet BioTherapeutics Holdings, Inc, a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues.
Further Reading
- Five stocks we like better than Sonnet BioTherapeutics
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Is Crypto Cool Again? What Stocks You Should Be Watching
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Why Call Options Volume for These 2 Stocks Spiked Together
- P/E Ratio Calculation: How to Assess Stocks
- MarketBeat Week in Review – 7/22 – 7/26
Receive News & Ratings for Sonnet BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonnet BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.